Uncategorized

Pixium Vision and research partners report progress in multiple areas with IRIS® and PRIMA during ARVO 2017 World Conference

by Business Wire • 2017/05/03 • 0 Comments

PARIS--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced its scientific program with multiple presentations of clinical and pre-clinical results at the Association for Research in Vision and Ophthalmology (ARVO) 2017 world congress in Baltimore 7 – 11 May, the main annual event for research and innovation in ophthalmolo

Full Story →

← Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt

Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma Patients →

Post navigation